Evald Høj Christiansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evald Høj Christiansen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ashkan Eftekhari
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication - Bent Raungaard
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication - Charlotte Glinge
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication - Christian Juhl Terkelsen
Department of Cardiology, Aarhus University Hospital , Aarhus
1 shared publication - Dan Eik Høfsten
Department of Cardiology, The Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
1 shared publication - Frants Pedersen
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Inge Lehmanns Vej 7, Copenhagen 2100
1 shared publication
Latest Publications
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e015369
10-Year Outcomes of Deferred or Conventional Stent Implantation in Patients With STEMI (DANAMI-3-DEFER)
BACKGROUND: Primary percutaneous coronary intervention (PCI) with stenting is recommended in ST-segment–elevation myocardial infarction. Immediate stenting may cause distal embolization, microvascular damage, and flow disturbances, leading to adverse outcomes. We report the 10-year clinical outcomes of deferred stenting versus conventional PCI in patients with ST-segment–elevation myocardial infarction. METHODS: We conducted a 10-year follow-up study of the open-label, randomized DANAMI-3-DEFER trial (Third Danish Study of Optimal Acute Treatment of Patients With STEMI – Deferred Stent Implantation Versus Conventional Treatment), conducted in 4 PCI centers in Denmark. Patients with ST-segment–elevation myocardial infarction and acute chest pain 24 hours after the index procedure or conventional PCI with immediate stenting. In the deferred group, immediate stable Thrombolysis in Myocardial Infarction flow II to III was established, and intravenous administration of either a glycoprotein IIb/IIIa antagonist or bivalirudin for >4 hours after the index procedure was recommended. The primary outcome was a composite of hospitalization for heart failure or all-cause mortality. Key secondary outcomes included individual components of the primary outcome and target vessel revascularization. RESULTS: Of 1215 patients, 603 were randomized to deferred stenting and 612 to conventional PCI. After 10 years, deferred stenting did not significantly reduce the primary composite outcome (hazard ratio, 0.82 [95% CI, 0.67–1.02]; P =0.08). In the deferred group, 124 (24%) died versus 150 (25%) in the conventional PCI group (hazard ratio, 0.95 [95% CI, 0.75–1.19]). Hospitalization for heart failure was lower in patients treated with deferred stenting compared with conventional PCI (odds ratio, 0.58 [95% CI, 0.39–0.88]). Target vessel revascularization was similar in both groups (odds ratio, 1.20 [95% CI, 0.81–1.79]). CONCLUSIONS: Deferred stenting did not reduce all-cause mortality or the composite primary outcome after 10 years but reduced hospitalization for heart failure compared with conventional PCI. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01435408.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e015369
Open Access10-Year Outcomes of Deferred or Conventional Stent Implantation in Patients With STEMI (DANAMI-3-DEFER)
BACKGROUND: Primary percutaneous coronary intervention (PCI) with stenting is recommended in ST-segment–elevation myocardial infarction. Immediate stenting may cause distal embolization, microvascular damage, and flow disturbances, leading to adverse outcomes. We report the 10-year clinical outcomes of deferred stenting versus conventional PCI in patients with ST-segment–elevation myocardial infarction. METHODS: We conducted a 10-year follow-up study of the open-label, randomized DANAMI-3-DEFER trial (Third Danish Study of Optimal Acute Treatment of Patients With STEMI – Deferred Stent Implantation Versus Conventional Treatment), conducted in 4 PCI centers in Denmark. Patients with ST-segment–elevation myocardial infarction and acute chest pain 24 hours after the index procedure or conventional PCI with immediate stenting. In the deferred group, immediate stable Thrombolysis in Myocardial Infarction flow II to III was established, and intravenous administration of either a glycoprotein IIb/IIIa antagonist or bivalirudin for >4 hours after the index procedure was recommended. The primary outcome was a composite of hospitalization for heart failure or all-cause mortality. Key secondary outcomes included individual components of the primary outcome and target vessel revascularization. RESULTS: Of 1215 patients, 603 were randomized to deferred stenting and 612 to conventional PCI. After 10 years, deferred stenting did not significantly reduce the primary composite outcome (hazard ratio, 0.82 [95% CI, 0.67–1.02]; P =0.08). In the deferred group, 124 (24%) died versus 150 (25%) in the conventional PCI group (hazard ratio, 0.95 [95% CI, 0.75–1.19]). Hospitalization for heart failure was lower in patients treated with deferred stenting compared with conventional PCI (odds ratio, 0.58 [95% CI, 0.39–0.88]). Target vessel revascularization was similar in both groups (odds ratio, 1.20 [95% CI, 0.81–1.79]). CONCLUSIONS: Deferred stenting did not reduce all-cause mortality or the composite primary outcome after 10 years but reduced hospitalization for heart failure compared with conventional PCI. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01435408.